Charles River Laboratories (CRL) : Copper Rock Capital Partners reduced its stake in Charles River Laboratories by 0.56% during the most recent quarter end. The investment management company now holds a total of 310,280 shares of Charles River Laboratories which is valued at $24.8 Million after selling 1,747 shares in Charles River Laboratories according to a report filed by the company on Apr 5, 2016 with the SEC.Charles River Laboratories makes up approximately 2.18% of Copper Rock Capital Partners’s portfolio.
Other Hedge Funds, Including ,
On the company’s financial health, Charles River Laboratories reported $1.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 10, 2016. Analyst had a consensus of $0.94. The company had revenue of $353.90 million for the quarter, compared to analysts expectations of $349.22 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS.
Many Wall Street Analysts have commented on Charles River Laboratories. Charles River Laboratories was Upgraded by Wells Fargo to ” Outperform” on Jan 7, 2016.
Charles River Laboratories closed down -1.92 points or -2.34% at $79.98 with 4,43,242 shares getting traded on Monday. Post opening the session at $82.25, the shares hit an intraday low of $79.54 and an intraday high of $82.25 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.